Table 1.
Baseline characteristics and prior treatments of the overall population included in the whole body MRI study (N=21).
Q1: 1st quartile, Q3: 3rd quartile
| Clinical characteristics | Median (Q1, Q3) | Min, max |
|---|---|---|
| Hemoglobin (g/dL) | 10.9 (10.2, 11.5) | 9.2, 14.2 |
| Prostate Specific Antigen (ng/mL) | 411 (146, 806) | 19, 2949 |
| Alkaline Phosphatase (IU/L) | 147 (86, 363) | 54, 2652 |
| Lactate Dehydrogenase (IU/L) | 234 (176, 318) | 109, 862 |
| Albumin (g/dL) | 3.5 (3.1, 3.7) | 2.7, 4.0 |
| Circulating Tumor Cell count (number/7.5ml) | 46 (8, 102) | 3, 187 |
| Prior treatments | No. | % |
| Docetaxel | 21 | 100.0 |
| Cabazitaxel | 11 | 52.4 |
| Abiraterone acetate | 19 | 90.5 |
| Enzalutamide | 4 | 19.0 |
| Radium-223 | 1 | 4.8 |
| Bisphosphonates | 4 | 19.0 |
| Palliative radiotherapy to bone | 6 | 28.6 |
| Sites of metastatic disease | No. | % |
| Bone | 21 | 100 |
| Nodal | 12 | 57.1 |
| Liver | 6 | 28.6 |
| Lung | 5 | 23.8 |
| Bone only | 7 | 33.3 |